Oxagen Limited, a drug discovery and development company specializing in inflammation, announced that the recruitment for its double blind, randomised, placebo controlled Phase IIb clinical trial in asthma with OC000459, its lead oral CRTH2 (DP2) antagonist, has now been completed.

Scientists of Helmholtz Zentrum München and the Center of Allergy and Environment (ZAUM) of Technische Universität München have discovered a new type of immune cells – the Th22 cells – which can protect the body against inflammation and aid in tissue repair. In the current online issue of the Journal of Clinical Investigation, Dr. Stefanie [...]

Every holiday season, millions of Americans travel through the nation’s airports, seaports, and train stations to spend time with loved ones. Special holiday get-togethers – and traveling itself – bring people close together but also provide an ideal way for illness to spread. To help travelers avoid the flu this holiday season, the Centers for [...]

The newly discovered Th22 cells are a previously unknown subset of T helper cells. T helper cells are white blood cells that help activate other immune cells when the body is infected by viruses or bacteria. At the same time they help the body to tolerate own tissue and to prevent or curb inflammation.

To help bring greater certainty to the measurement of medication levels in a patient’s bloodstream for three drugs with narrow therapeutic ranges, the U.S. Pharmacopeial Convention (USP) is releasing new certified reference materials (CRMs).